Relationship of complement activation route with clinical manifestations in Japanese patients with systemic lupus erythematosus: A retrospective observational study

References

• Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058–66.
   PubMedGoogle Scholar
• Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140–4.
   PubMedGoogle Scholar
• Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science. 1996;272(5258):50–3.
   PubMedGoogle Scholar
• Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA. 1996;93(8):3357–61.
   PubMedGoogle Scholar
• Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, et al. Contribution of innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001;2(8):739–45.
   PubMedGoogle Scholar
• Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002;169(4):2126–33.
   PubMedGoogle Scholar
• Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, et al. A critical role for complement in maintenance of self-tolerance. Immunity. 1998;9(5):721–31.
   PubMedGoogle Scholar
• Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol. 2000;74:61–88.
   PubMedGoogle Scholar
• Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol. 2006;176(3): 1305–10.
   PubMedGoogle Scholar
• Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008;223:300–16.
   PubMed Web of Science ®Google Scholar
• Jokiranta TS, Zipfel PF, Fremeaux-Bacchi V, Taylor CM, Goodship TJ, Noris M. Where next with atypical hemolytic uremic syndrome? Mol Immunol. 2007;44(16):3889–900.
   PubMedGoogle Scholar
• Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007;16(3):204–12.
   PubMedGoogle Scholar
• Donoso LA, Kim EE, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51(2):137–52.
   PubMed Web of Science ®Google Scholar
• Humbles AA, Lu B, Nisson CA, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature. 2000;406(6799):998–1001.
   PubMedGoogle Scholar
• Krug N, Tschemig T, Erpenbeck VJ, Hohlfeld JM, Köhl J. Complement factors C3a and C5a are increased in brochoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1841–3.
   PubMedGoogle Scholar
• Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol. 1999;21(4):480–9.
   PubMedGoogle Scholar
• Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170(3): 1517–23.
   PubMedGoogle Scholar
• Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105(10):1363–71.
   PubMedGoogle Scholar
• Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005; 16(5):1392–403.
   PubMedGoogle Scholar
• Schwertz R, Rother U, Anders D, Gretz N, Schärer K, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol. 2001;12(3):166–72.
   PubMedGoogle Scholar
• Meri S, Koistinen V, Miettinen A, Törnroth T, Seppälä IJ. Activation of the alternative pathway of complement by monoclonal lamda light chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175(4):939–50.
   PubMedGoogle Scholar
• Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH. Prevention of cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2(1): 64–8.
   PubMedGoogle Scholar
• Tichenor JR, Bledsoe LB, Opsahl MS, Cunningham DS. Activation of complement in humans with a first-trimester pregnancy loss. Gynecol Obstet Invest. 1995;39(2):79–82.
   PubMedGoogle Scholar
• Mao D, Wu X, Deppong C, Friend LD, Dolecki G, Nelson DM, Molina H. Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. Immunity. 2003;19(6):813–22.
   PubMedGoogle Scholar
• Liu CC, Ahearn JM. Complement and systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois’ Lupus Erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 216.
   Google Scholar
• Bomberdier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Study in SLE. Arthritis Rheum. 1992;35(6):630–40.
   PubMedGoogle Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
   PubMed Web of Science ®Google Scholar
• Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–11.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
   PubMed Web of Science ®Google Scholar
• Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13(3):486–9.
   PubMed Web of Science ®Google Scholar
• Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74(1): 1–9.
   PubMed Web of Science ®Google Scholar
• Man BL, Mok CC. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus. 2005;14(10):822–6.
   PubMedGoogle Scholar
• Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35(6): 368–78.
   PubMedGoogle Scholar
• Du Y, Mohan C. Pathogenesis of lupus nephritis. In: Lahita RG, Tsokos G, Buyon JP, Koike T, editors. Systemic Lupus Erythematosus. 5th ed. San Diego: Elsevier; 2011. p. 455–6.
   Google Scholar
• Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52(7):2120–4.
   PubMedGoogle Scholar
• Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195(2):211–20.
   PubMedGoogle Scholar
• Xu C, Mao D, Holers VM, Palanca B, Chang AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000;287(5452):498–501.
   PubMedGoogle Scholar
• Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis. 2002;61(Suppl 2):ii46–50.
   Google Scholar
• Girarde G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003;112(11): 1644–54.
   PubMedGoogle Scholar
• Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol. 2005;42(1):87–97.
   PubMedGoogle Scholar
• Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T, et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis. 2009;68:1030–5.
   PubMed Web of Science ®Google Scholar
• Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol. 1992;10(5):455–60.
   PubMedGoogle Scholar
• Navratil JS, Manzi S, Kao AH, Krishnaswami S, Liu CC, Ruffing MJ, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54(2):670–4.
   PubMedGoogle Scholar
• Peershke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway f human complement. J Thromb Haemost. 2006;4(9):2035–42.
   PubMedGoogle Scholar
• Peershke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: Implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47(13):2170–5.
   PubMedGoogle Scholar
• Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97.
   PubMedGoogle Scholar
• Inai S, Akagaki Y, Moriyama T, Fukumori Y, Yoshimura K, Ohnoki S, Yamaguchi H. Inherited deficiencies of the late-acting complement components other than C9 found among healthy blood donors. Int Arch Allergy Appl Immunol. 1989;90(3):274–9.
   PubMedGoogle Scholar
• Nishizaka H, Horiuchi T. Complement deficiency. In: Ohi H, Kinoshita T, Matsushita M, editors. Introduction to Complement. 1st ed. Tokyo: Medical View Co., Ltd; 2012. pp. 130–8. (Japanese).
   Google Scholar
• Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Birmingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun. 2004;7:98–132.
   PubMedGoogle Scholar
• Naves M, Hajeer AH, Teh LS, Davies EJ, Ordi-Ros J, Perez-Pemen P, et al. Complement C4B null allele status confers risk for systemic lupus erythematosus in a Spanish population. Eur J Immunogenet. 1998;25(4):317–20.
   PubMedGoogle Scholar